AFP and liver cancer: In order to evaluate the performance of the 3-RNA panel for AFP-negative patients, we used 8 AFP-positive (AFP > 400 ng/mL) liver cancer patients as a positive training set, as well as 26 HDs and 24 chronic hepatitis B (CHB) patients as a negative training set, to generate a random forest model.